Live Breaking News & Updates on After Previous

Stay updated with breaking news from After previous. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lazertinib Versus Gefitinib as First-line Treatment in EGFR-mutated Advanced NSCLC

1. Progression-free survival was longer in the lazertinib group vs the gefitinib group (20.6 months vs 9.7 months, with HR 0.45), however, OS data were immature. 2. Treatment-related adverse events were similar across both groups, however, lazertinib had higher rates of parasthesia and pruritus but lower levels of ALT elevations and diarrhea. Evidence Rating Level: ....

Rating Level , Patients With Advanced , After Previous , Median Dor ,